Compounds

A process for preparing a compound of formula (I):

• or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, wherein:
• A1 represents a substituted or unsubstituted, single ring aromatic heterocyclyl group having 4 to 7 ring atoms and comprising up to 4 hetero atoms selected from oxygen, sulphur and nitrogen, the substituents for the heterocyclyl group being up to 4 substituents selected from the group consisting of:
• C1-12-alkyl, C1-12-alkoxy, aryl and halogen or any two substituents on adjacent carbon atoms, together with the carbon atoms to which they are attached, may form an aryl group, and wherein the carbon atoms of the aryl group represented by the said two substituents may themselves be substituted or unsubstituted;
• R1 represents a hydrogen atom, a C1-12-alkyl group, a C1-6-alkylcarbonyl group, an aryl-C1-12-alkyl group, the aryl moiety being substituted or unsubstituted, or a substituted or unsubstituted aryl group;
• any aryl group being phenyl or naphthyl optionally substituted with up to five groups selected from halogen, C1-12-alkyl, phenyl, C1-12-alkoxy, halo-C1-12-alkyl, hydroxy, amino, nitro, carboxy, C1-12-alkoxycarbonyl, C1-12-alkoxycarbonyl-C1-12-alkyl, C1-12-alkylcarbonyloxy, and C1-12-alkylcarbonyl;
• R2 and R3 each represent hydrogen, or R2 and R3 together represent a bond;
• A2 represents a benzene ring having three optional substituents which may be selected from halogen, substituted or unsubstituted alkyl or alkoxy, substituents for the alkyl group being selected from the group consisting of halogen, C1-12-alkyl, phenyl, C1-12-alkoxy, halo-C1-12-alkyl, hydroxy, amino, nitro, carboxy, C1-12-alkoxycarbonyl, C1-12-alkoxycarbonyl-C1-12-alkyl, C1-12-alkylcarbonyloxy, and C1-12-alkylcarbonyl;
• and
• n represents an integer in the range of from 2 to 6;
• wherein the process comprises reacting a compound of formula (III):
• wherein R2, R3 and A2 are as defined in relation to formula (I), and Ra is a moiety convertible to a moiety of formula (f):
• wherein R1, A1, and n are as defined in relation to formula (I), with an appropriate reagent capable of converting Ra to the said moiety (f);
• and thereafter optionally carrying out one or more of the following steps:
• (i) converting a compound of formula (I) to a further compound of formula (I);
• and/or
• (ii) preparing a pharmaceutically acceptable salt of the compound of formula (I) and/or a pharmaceutically acceptable solvate thereof.